

Elevating body temperature to reduce chronic low-grade inflammation: a welcome strategy for those unable to exercise?

Sven P. Hoekstra^{1,2}, Nicolette C. Bishop¹, Christof A. Leicht^{1,2}

¹ School of Sport, Exercise, and Health Sciences; Loughborough University; Loughborough; UK

² The Peter Harrison Centre for Disability Sport; Loughborough University; Loughborough; UK

Abstract

Chronic low-grade inflammation is increasingly recognised in the aetiology of a range of chronic diseases, including type 2 diabetes mellitus and cardiovascular disease, and may therefore serve as a promising target in their prevention or treatment. An acute inflammatory response can be induced by exercise; this is characterised by the acute increase in pro-inflammatory markers that subsequently stimulate the production of anti-inflammatory proteins. This may help explain the reduction in basal concentrations of pro-inflammatory markers following chronic exercise training. For sedentary populations, such as people with a disability, wheelchair users, or the elderly, the prevalence of chronic low-grade inflammation-related disease is further increased above that of individuals with a greater capacity to be physically active. Performing regular exercise with its proposed anti-inflammatory potential may not be feasible for these individuals due to a low physical capacity or other barriers to exercise. Therefore, alternatives to exercise that induce a transient acute inflammatory response may benefit their health. Manipulating body temperature may be such an alternative. Indeed, exercising in the heat results in a larger acute increase in inflammatory markers such as interleukin-6 and heat shock protein 72 when compared with exercising in thermoneutral conditions. Moreover, similar to exercise, passive elevation of body temperature can induce acute increases and chronic reductions in inflammatory markers and positively affect markers of glycaemic control. Here we discuss the potential benefits and mechanisms of active (i.e., exercise) and passive heating methods (e.g., hot water immersion, sauna therapy) to reduce chronic low-grade inflammation and improve metabolic health, with a focus on people who are restricted from being physically active.

Keywords: hyperthermia, passive heating, cytokines, heat shock protein, glucose metabolism

Chronic low-grade inflammation and chronic disease

Introduction

Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are associated with small, yet sustained elevations in circulating levels of pro-inflammatory proteins, a state called chronic low-grade inflammation (11). Causative links between inflammation and the aetiology of those diseases have been suggested (34). For example, in T2DM, chronically elevated plasma concentrations of pro-inflammatory cytokines can impair insulin sensitivity by affecting insulin signalling, potentially through inhibition of C-Jun N-Terminal Kinase (JNK) (72). Indeed, it has been shown that attenuation of JNK activity is associated with protection from insulin resistance in mice (63). For CVD, vascular integrity may be impaired by pro-inflammatory cytokines, facilitating the infiltration of macrophages through the vascular wall to form atherosclerotic plaques (9). Gene knockout studies in mice provide experimental evidence that the actions of tumour necrosis factor α (TNF- α) lead to an increase of plaque formation (19). This aligns with observational epidemiological data that show a positive association between pro-inflammatory markers and future CVD events (147).

These examples indicate that targeting inflammatory pathways might help to prevent and treat chronic inflammatory diseases. The last two decades have seen a host of studies investigating the anti-inflammatory effects of lifestyle interventions, such as exercise (54). Inflammation is multi-faceted in nature. Here we introduce two categories of inflammatory markers that are relatively well studied in the context of exercise, temperature and chronic low-grade inflammation: cytokines and heat shock protein. Referring to literature focused on exercise in addition to passive heating, we then discuss how temperature can affect chronic inflammation, providing rationale for the potential benefits of elevated temperature in chronic disease prevention.

Cytokines

It is recognised that a surplus of body fat is an independent risk factor for T2DM and CVD (151). Confirming the interactions between obesity and inflammation, it has been demonstrated that basal circulating interleukin (IL)-6 concentration in obese individuals is elevated, and that weight loss can reduce the concentration of this risk marker (32, 96). A mechanistic explanation lies in visceral adipose tissue and the residing macrophages within that are a major source of circu-

Corresponding author:

Christof A. Leicht, c.a.leicht@lboro.ac.uk

lating IL-6 at rest (11). Further mechanistic evidence is derived from the associations between obesity, increased intestinal permeability and inflammation (125). Both a high fat diet and increases in body mass increase intestinal bacterial species' DNA in adipose tissue, which correlates with TNF- α mRNA expression in adipose tissue (2). The importance of inflammatory pathways in the aetiology of T2DM is further underlined by data demonstrating that inhibition of pro-inflammatory pathways by knocking out the nuclear factor kappa B (NF- κ B) (5) and JNK (65) pathways disrupts the link between obesity and insulin resistance in obese mice. In addition, pro-inflammatory cytokines can prevent tyrosine phosphorylation of IRS-1 upon activation of the insulin receptor and instead promote phosphorylation of IRS-1 on its serine residues, which leads to impaired insulin signalling (72). This might explain why blocking the actions of pro-inflammatory cytokines using anti-TNF- α treatments can improve insulin sensitivity (73).

The cytokine interleukin (IL)-6 has been extensively studied in the context of chronic low-grade inflammation; however, to date, its causative role remains heavily debated (34, 121). Observational studies report a positive association between the chronic elevation of plasma IL-6 concentration and insulin resistance, atherosclerosis, T2DM and CVD (11, 34, 38, 120, 144), linking it with chronic disease. It is important, however, to appreciate the diverse actions of IL-6. For instance, infusion of IL-6 for 2 to 4 h does not alter (133) or even enhances insulin sensitivity (25). There are possible explanations for this discrepancy. Whereas transient increases in plasma IL-6 concentrations can acutely enhance insulin action via AMP-activated protein kinase activation and glucose transporter-4 (GLUT4) translocation (25), chronic increases may impair insulin signalling by inhibiting the phosphorylation of tyrosine residues on IRS-1 (34). In the context of T2DM, it is noteworthy that IL-6 production is upregulated in response to increased concentrations of TNF- α (135). Because the detrimental role of TNF- α in insulin sensitivity and vascular function is relatively well-established (34, 135), it has been suggested that IL-6 may serve as a bystander rather than having a direct impact on health (43). On the other hand, pharmacological blocking of the IL-6 receptor can alleviate symptoms of a range of inflammatory diseases, such as rheumatoid and juvenile idiopathic arthritis (76). However, this also brings about increased concentrations of cholesterol and worsening of insulin sensitivity (117). The exact function of IL-6 in the circulation may also depend on the receptors it binds to following appearance in the circulation. Several cell types (e.g., leukocytes, hepatocytes) express surface IL-6 receptors for *classic* IL-6 signalling, while IL-6 can also bind to soluble IL-6 receptors present in the circulation, after which the resulting complex can bind to cells that do not express the IL-6 receptor (e.g., skeletal muscle cells) in a process called trans-signalling. It is the latter signalling pathway that is suggested to be mainly associated with inflammation (53). Taken together, although the exact underlying mechanisms need further research, chronically elevated plasma IL-6 concentrations are associated with poor metabolic health (11, 34).

Monocytes contribute to the inflammatory profile as they are producers of pro-inflammatory cytokines by signalling

through their surface receptors, toll-like receptor (TLR)2, TLR4 and cluster of differentiation (CD) 14 (1, 7). By binding to the TLR-CD14 complex, pathogen-associated molecular patterns can trigger the production of cytokines such as IL-6 and TNF- α through the activation of the NF- κ B pathway (7). As a result, the expression of TLRs on the surface of monocytes has been suggested to be a marker for chronic-low grade inflammation (89), particularly TLR2 and TLR4 (47). Indeed, monocytes from individuals with T2DM express more TLR2 and TLR4 when compared with healthy controls (35).

In addition to the surface expression of TLRs, the inflammatory nature of monocytes can be characterised by their expression of CD14 and CD16. Using these two surface markers, monocytes can be divided into three subsets: classical monocytes (CD14⁺⁺CD16⁻), intermediate monocytes (CD14⁺⁺CD16⁺) and non-classical monocytes (CD14⁺CD16⁺⁺) (154). Interestingly, TLR4 expression is lowest in the classical subsets, as shown in patients with acute myocardial infarction (78) or stable angina pectoris (116). This might explain why a large proportion of intermediate and non-classical monocytes are associated with CVD, T2DM and other chronic diseases (103, 153), suggesting that the distribution of monocyte subsets can be used as a marker for chronic low-grade inflammation. Indeed, in response to an *in-vitro* stimulant (i.e., lipopolysaccharide (LPS)) non-classical and intermediate monocytes produce more of the pro-inflammatory cytokines TNF- α and IL-1 β than the classical subset (17, 110).

Heat shock protein

The presence of heat shock protein (HSP) has been confirmed in every eukaryotic cell type and HSP subtypes have been defined based on their molecular mass, ranging from the HSP10 to the HSP110 family. Notably, contrary to what the name might suggest, HSPs are not exclusively induced by heat but are responsive to a range of stressors including hyperthermia, oxidative stress and glycogen depletion (112). With regards to chronic low-grade inflammation, exercise and temperature, the HSP70 family, with its inducible subtype Hsp72, is most widely studied and is the HSP of focus in this review. Note that we use the nomenclature adopted by the Cell Stress Society International, in which HSP refers to the protein family, Hsp refers to the specific protein, and *hsp* refers to the gene and mRNA expression.

Intracellular Hsp72 (iHsp72) functions as a chaperone for protein folding and aids in the maintenance of homeostasis within cells (112). Indeed, the survival rate in mice subjected to heat shock is higher when iHsp72 expression is elevated by a prior non-lethal heat shock compared to control mice (84). When in homeostasis, Hsp72 is bound to heat shock factor-1 (HSF-1) in the cytosol, rendering this complex inactive. In response to physiological stress or inflammation, these molecules are uncoupled, allowing HSF-1 to translocate to the nucleus and activate heat shock elements on the heat shock protein gene. As a result, the transcribed *hsp72* mRNA then leads to an increased Hsp72 protein expression in the cytosol (82). Expression of Hsp72 and its association with metabolic health has been assessed in a variety of cell types, with levels in

leukocytes, adipose tissue and skeletal muscle tissue having gained most attention in the context of chronic low-grade inflammation and metabolic health (63). It is suggested that iHsp72 exerts its anti-inflammatory actions by blocking the activity of the JNK and NF- κ B pathways, reducing the production of pro-inflammatory cytokines and enhancing insulin sensitivity (30, 63). Indeed, it has been shown in cell culture experiments that JNK activation is reduced in cells overexpressing Hsp72 (48), and that a high iHsp72 expression prevents the activation of NF- κ B and subsequent TNF- α gene transcription (106).

A growing body of evidence supports the importance of HSP in the aetiology of T2DM and CVD (63, 71). In humans, iHsp72 expression in skeletal muscle and adipose tissue is lower in those with T2DM and non-alcoholic fatty liver disease when compared with healthy controls (20, 24, 62). In murine models, Hsp72 knock-out mice develop insulin resistance and obesity (63), and mice in which iHsp72 is overexpressed are protected against the deleterious effects of high fat overfeeding on insulin sensitivity (61). Protection from insulin resistance in mice appears to be associated with the attenuation of JNK. Interestingly, in this particular study JNK attenuation was achieved by heat therapy (63). Moreover, pharmacologically restoring Hsp72 expression induces an 85% increase in glucose clearance rate during intravenous glucose infusion in Hsp72-deficient monkeys (80).

Whereas animal studies have provided compelling evidence of the influence of iHsp72 in skeletal muscle on metabolic health (30, 80), the protective effect of an elevated expression of iHsp72 in immune cells is less clear. Compared with other leukocyte subsets, iHsp72 in monocytes is most responsive to stress and iHsp72 expression shows a dose-response relationship with incubation temperature in isolated cell suspensions (8). Monocytes produce a range of pro-inflammatory cytokines when activated including TNF- α and IL-1 β (36); iHsp72 expression in this cell type may therefore directly affect the inflammatory profile of an individual. In addition, and similar to skeletal muscle, monocytes are insulin-sensitive. Their behaviour may therefore serve as surrogate measure for peripheral insulin sensitivity (128). Simar et al. (129), Singh et al. (130) and Njemini et al. (111) found a reduction in resting iHsp72 expression in monocytes as a result of ageing, a process associated with the development of chronic low-grade inflammation (15). Furthermore, increased basal expression of iHsp72 in monocyte-derived macrophages reduces the production of TNF- α and IL-1 β in response to *in-vitro* LPS stimulation (36). This finding indicates an anti-inflammatory function of iHsp72 in this cell type.

Hsp72 is also released into the circulation, where its function differs from Hsp72 present within the cell. The tissues that excrete Hsp72 are not fully identified, but there is evidence that the liver, the brain and leukocytes release Hsp72 into the circulation through passive - as well as active - mechanisms (75). In a study using exercise as a stressor, Febbraio et al. (42) showed that skeletal muscle does not contribute to circulating eHsp72 concentrations. In contrast to the anti-inflammatory actions of iHsp72, extracellular Hsp72 (eHsp72) can

activate monocytes through the TLR4/CD14 complex, inducing the production of pro-inflammatory cytokines (6). Indeed, elevated basal levels of eHsp72 are linked to impaired insulin sensitivity (28, 35, 85) and the development of atherosclerosis in individuals with hypertension (119). In further support of its potential role in chronic low-grade inflammation, resting eHsp72 concentrations strongly correlate with resting serum TNF- α and CRP concentrations in elderly individuals (111). Thus, by stimulating the production of pro-inflammatory cytokines in circulating immune cells, eHsp72 may exacerbate chronic low-grade inflammation and exert a negative effect on health. As the extracellular, pro-inflammatory, function of Hsp72 appears to differ from the cytoprotective function when present in the cell, it has been suggested that the ratio between extra- and intracellular Hsp72 expression could be a determinant for insulin resistance and T2DM risk (86).

Despite the cross-sectional data suggesting a negative role of eHsp72 on several aspects of health, evidence for its potential to induce pro-inflammatory cytokine release in monocytes and other leukocytes is equivocal (75). It has been suggested that the activation of monocytes following *in-vitro* incubation with eHsp72 can be the consequence of contamination with endotoxins, as opposed to the effect of eHsp72 itself (14, 49). For example, incubating monocyte-derived dendritic cells with endotoxin-free Hsp70 does not induce an acute inflammatory response (14). Moreover, pre-incubation of eHsp72 with polymyxin-B to block the actions of the contaminant LPS abolishes the production of pro-inflammatory cytokines in macrophages (49). Therefore, future *in-vitro* research on the mechanistic actions of eHsp72 should carefully control for possible contamination by endotoxins.

The anti-inflammatory effects of exercise – and the role of temperature

The following evidence derived from the exercise literature helps to understand and partly informs the inflammatory response to hyperthermia. It is heavily summarised; for a broader view on exercise and inflammation, the reader is directed to previous excellent reviews, for example by Gleeson et al. (54) and Petersen and Pedersen (118).

1. Acute exercise

If of sufficient intensity and duration, a bout of exercise induces an acute inflammatory and subsequent anti-inflammatory response, which is thought to be partly responsible for the protective effects of regular exercise (54, 118). IL-6 responds most dramatically to acute exercise and has been suggested to be a main driver of the anti-inflammatory effects of exercise, because the acute post-exercise peak of IL-6 is followed by elevated anti-inflammatory cytokine concentrations (118). Indeed, infusion of recombinant human IL-6 in healthy humans at rest shows that IL-6 independently triggers the production of anti-inflammatory cytokines such as IL-1ra or IL-10, and it increases plasma concentrations of cortisol, a hormone with anti-inflammatory properties (132). Furthermore, acute exercise can increase iHsp72 (108,

112) and eHsp72 concentrations (148), while suppressing TNF- α and IL-1 production (117). The distribution of monocyte subsets within the peripheral circulation is also affected by acute exercise. Most studies report an acute increase in intermediate and non-classical monocytes directly following the cessation of exercise (33, 69, 136), but increases in classical monocytes following exercise have also been reported (94, 103). Potentially reflecting the change in circulating monocyte subsets, reduced monocyte TLR expression in the two-hour recovery period following exercise has been reported (89), which may help explain the mechanisms behind the altered inflammatory profile following acute exercise.

The inflammatory response to exercise is affected by both exercise duration and intensity (117). Importantly, in the context of this review, the increase in body temperature contributes to this relationship. Exercise in the heat results in a greater inflammatory response when compared with exercise in thermoneutral or cold conditions (44, 51, 88, 122, 131). Moreover, clamping core temperature (T_{core}) by cycling in cold water can abolish the acute IL-6 response (122). The amplified acute cytokine response following exercise in the heat may be partly mediated by the increased plasma catecholamine concentrations (122) and carbohydrate utilisation when compared with exercise in thermoneutral or cold conditions (45).

2. Regular exercise

Regular exercise is protective against the development of T2DM and CVD (95, 126). Cross-sectional and longitudinal evidence suggests that regular physical activity can reduce chronic low-grade inflammation, as indicated by lower basal circulating concentrations of the inflammatory risk factors IL-6, eHsp72, and numbers of intermediate and non-classical monocytes (16, 54, 59, 152). Possible candidates to explain improvements in the inflammatory profile after exercise training are reductions in visceral adipose tissue (producing pro-inflammatory cytokines at rest) (40), reduced TLR expression on immune cells (47) and changes in the number and phenotype of circulating cells and immune cells residing in tissue (139).

3. Heat acclimation studies

Heat acclimation studies provide some insight on the inflammatory effect of exercise training in the heat (reviewed by Amorim et al. (4)). Basal iHsp72 expression has been particularly studied as a mediator for the enhanced heat tolerance after heat acclimation (87): Whereas three days of heat acclimation do not increase basal iHsp72 expression in peripheral blood mononuclear cells (99), ten days of heat acclimation seem sufficient to increase basal iHsp72 expression in peripheral blood mononuclear cells (3, 105). Furthermore, the link between iHsp72 and markers of metabolic health, such as insulin sensitivity (63), suggests that heat acclimation-type exercise training may have wider-reaching effects than on exercise performance alone.

Who benefits from passive heating interventions?

Over the past decade there has been an alarming increase in number of people suffering from T2DM and CVD in the general population (150). The prevalence of these diseases is even higher in those with obesity (12), the elderly (31), or individuals with a physical disability, such as spinal cord injury (SCI) (13). Given the anti-inflammatory benefits of exercise outlined briefly above, it is unsurprising that a common trait of these populations is a reduced physical capacity. Despite this, there is still promise for exercise interventions. Even low-intensity exercise interventions such as regular walking can induce improvements in inflammatory markers in at-risk populations (142). For populations restricted to upper-body exercise modalities (e.g., wheelchair users) it is worth noting that this can induce an acute inflammatory response despite the smaller active muscle mass when compared with lower body exercise (67). Indeed, comparable inflammatory responses have been reported between upper and lower body exercise matched for relative intensity (94). Further, cross-sectional evidence (107), as well as some (10, 124) - but not all (140) - longitudinal upper-body exercise interventions indicate that upper body exercise can reduce inflammatory risk markers in SCI. Metabolic markers such as fasting glucose and insulin in people with SCI are also positively affected by physical activity (23).

Because reductions in physical *capacity* per se do not preclude the inflammatory effects of exercise, it is conceivable that the below-average physical *activity* levels in these at-risk populations (100, 137) contribute to their elevated disease risk. Indeed, environmental, social, and physical barriers to exercise have been identified (97, 143), which may go some way to explain the increased risk for chronic disease. Furthermore, for some populations, exercise of adequate intensity and duration may not be feasible or tolerable. These populations include those with acute injuries (e.g., musculoskeletal injuries, patients recovering from surgery), movement restrictions (e.g., due to obesity, spasticity), secondary complications to chronic disease (e.g., diabetic foot for T2DM, pressure sores for conditions leading to immobility), or cognitive impairments (e.g., dementia). An alternative or addition to exercise may hence represent a welcome strategy for these individuals. Because the acute inflammatory response to exercise is partly mediated by the rise in body temperature (88, 149), it is conceivable that passive heating strategies have the potential to improve the inflammatory profile. Similar to exercise, these strategies have the benefit of being low-cost, non-pharmacological interventions, reducing the financial strain on health-care providers.

The acute inflammatory response to passive heating

There are several ways to increase body temperature passively in humans, of which sauna bathing and hot water immersion (HWI) are the most commonly used. These methods are associated with a range of positive health outcomes, such as weight loss (70), improved sleep quality (37) and vascular

function (21, 27). Nevertheless, the potential of passive heating to reduce chronic low-grade inflammation and improve metabolic health has received relatively scarce attention.

Cytokines

It is suggested that contracting muscle is responsible for the increased circulating concentrations of IL-6 following exercise (134). Animal studies show that the IL-6 production in skeletal muscle increases following passive heat stress as well (146). Welc et al. (145) demonstrated that the upregulation of IL-6 production may be the consequence of HSF-1 activation. Another suggested mechanism for IL-6 release from the muscle in response to hyperthermia is through increased calcium influx after activation of the thermosensitive transient receptor potential 1 (113). Although these studies have provided rationale to study passively elevating body temperature in the context of chronic low-grade inflammation, it should be noted that in animal studies T_{core} is increased to a much larger extent than considered safe in human participants (50, 127, 146). This could make passive heating interventions less potent inducers of an acute inflammatory response in humans. For example, Gupte et al. (57) kept the T_{core} of mice between 41.0° and 41.5°, while in human studies the maximal attained T_{core} during HWI remained between 38° and 39° (41, 66, 114). Furthermore, due to the difference in size between species - and concomitant higher inertia in T_{core} during passive heating in larger species - T_{core} of humans takes considerably longer than that of small animals to increase to a given threshold. This is another important difference between human and animal research to date, in addition to the often reported higher T_{core} investigated in animals.

An overview of studies investigating the acute response of inflammatory markers following passive heating is provided in Table 1. Despite smaller increases in T_{core} during passive heating in human compared with animal studies, 1–2 h HWI induces an acute circulating IL-6 response in humans (41, 66, 88, 93). Consistent with exercise studies (46), this acute IL-6 response appears to be dose-dependent. Laing et al. (88) reported a ~12

fold increase in IL-6 immediately following 2 h HWI in water set at 38.5° while 1 h HWI only results in a ~2–3 fold increase in plasma IL-6 concentration (41, 66, 93).

Heat shock protein

The activation of HSF-1 by passive heating not only results in increased IL-6, but also increased iHsp72 production (146). Raising the temperature of human blood ex-vivo indeed results in an acute increase in iHsp72 expression (68), which is consistent with findings in animal passive heating studies (57, 79). In Vervet monkeys, maintaining T_{core} between 39° and 41° for 30 min using HWI results in a significant increase in *hsp72* expression in skeletal muscle. In addition, maintaining T_{core} of rats around 41.0–41.5° for 20 min using a thermal blanket leads to a ~three-fold increase in iHsp72 protein

Table 1. The acute effect of passive heating on inflammatory markers in humans.

Reference	Design	Population	Main outcomes
Brunt et al., 2018 (22)	1 h HWI up to the shoulder in water set at 40.5°C	Healthy inactive men (N=6) and women (N=4) and sex-matched controls (N=10)	Serum concentration eHsp72 ↔, IL-6 ↑; peripheral blood mononuclear cell iHsp72 ↑
Faulkner et al., 2017 (41)	1 h HWI up to the waist in water set at 40°C	Healthy men (N=14)	Plasma concentration eHsp72 ↑, IL-6 ↑
Hafen et al., 2018 (58)	2 h heating of skeletal muscle using pulsed wave diathermy	Healthy sedentary men (N=10) and women (N=10)	Skeletal muscle iHsp72 ↔
Hashisaki et al., 2018 (60)	1 h in water-perfused suit to achieve 1°C rise in T_{core}	Individuals with spinal cord injury (N=19) and able-bodied controls (N=8)	Serum concentration IL-6 ↑, TNF-α ↔
Hoekstra et al., 2018 (66)	1 h HWI up to the neck in water set at 39°C	Healthy overweight sedentary men (BMI = 31±4 kg/m ² ; N=10)	Plasma concentration eHsp72 ↔, IL-6 ↑; monocyte iHsp72 ↔
Iguchi et al., 2012 (74)	30 min in room set at 73°C	Healthy men (N=13) and women (N=12)	Plasma concentration eHsp72 ↑
Laing et al., 2008 (88)	2 h HWI in water set at 38.5°C	Healthy men (N=13)	Serum concentration IL-6 ↑
Leicht et al., 2015 (93)	1 h HWI up to the neck in water set 2°C higher than resting T_{core}	Men with spinal cord injury (N=7) and able-bodied controls (N=8)	Plasma concentration IL-6 ↑, IL-1ra ↑, TNF-α ↔
Morton et al., 2007 (109)	1 h HWI of one leg in water set at 45°C	Healthy men (N=7)	Skeletal muscle iHsp72 ↔
Oehler et al., 2001 (114)	2 h HWI up to the neck in water set at 39.5°C	Healthy men (N=6) and women (N=6)	Monocyte iHsp72 ↑
Whitham et al., 2007 (149)	2 h HWI in water set at 38.5°C; control at 35°C	Healthy men (N=11)	Plasma concentration eHsp72 ↔
Zychowska et al., 2017 (156)	30 min sauna bathing at 98°C	Healthy men (N=18)	leukocytes: <i>hsp72</i> mRNA expression ↔, IL-6 ↔, IL-10 ↔

Abbreviations: eHsp72, extracellular heat shock protein 72; HWI, hot water immersion; iHsp72, intracellular heat shock protein 72; IL, interleukin; IL-1ra, interleukin-1 receptor antagonist; mRNA, messenger ribonucleic acid

expression in skeletal muscle when compared with control (57). Of note, the acutely increased iHsp72 expression in these two studies was also associated with improved insulin sensitivity.

Despite promising evidence from animal and isolated tissue studies, the iHsp72 response in human whole-body models shows mixed results. Some of the variation may be confounded by the tissue analysed, with relatively few studies investigating skeletal muscle iHsp72 following passive heat stress. This lack of studies may be related to the invasive nature of skeletal muscle sampling. Harvesting monocytes by venepuncture is relatively easy in comparison, and some of the human evidence on passive heating is therefore based on monocyte iHsp72 (66, 114), due to monocyte responsiveness to heat stress (8). Although the acute iHsp72 response to exercise in total leukocytes is similar to the response in skeletal muscle (141), comparing results from studies investigating different cell/tissue types must be done with due caution.

To date, only four studies have investigated the acute iHsp72 response to HWI in humans. These studies found no increase in skeletal muscle (109) or monocytes (66) after 1 h, but an increase in PBMC iHsp72 after 1 h (22), and an increase in monocyte iHsp72 expression after 2 h HWI (114). Time is a likely determinant of the iHsp72 response. This is supported by Gibson et al. (52), who demonstrated that T_{core} needs to be maintained above 38.5° for at least 27 min to induce the upregulation of *hsp72* expression following exercise. The extent to which T_{core} is elevated is a likely additional explanatory factor. T_{core} increased by approximately 1.7–2.0°C in the study showing increases in monocyte iHsp72 expression (22, 114), whereas the increase was ~1.5°C in the studies showing no change in this parameter (66, 109).

There are limited data about the potential of HWI to induce an acute increase in eHsp72 concentration in humans. Faulkner et al. (41) reported a similar increase in eHsp72 concentration following HWI when compared with exercise matched for heat production. The elevation of muscle temperature was the strongest predictor for the eHsp72 response, explaining 27% of its variance (41). Passive heating by 30 min of sauna bathing, resulting in a 0.8° T_{core} increase, also leads to the elevation of eHsp72 concentrations (74). In contrast, Brunt et al. (22), Hoekstra et al. (66) and Whitham et al. (149) found no significant acute change in eHsp72 following HWI in water set at 38.5–40.5°. Therefore, partly due to the lack of a control condition in some studies and the different designs across studies, the potential of passive heating to elevate eHsp72 concentrations remains equivocal.

Chronic adaptations to passive heating interventions

Acute studies have confirmed the potential of HWI to induce an inflammatory response (41, 66, 88, 93, 114), which has led to the suggestion that chronic HWI treatment may help to reduce chronic low-grade inflammation and improve metabolic health (71, 86, 104, 138). Although there are currently limited human data to support this notion, animal studies provide

some insight into the efficacy of chronic passive heat therapy and the few human studies available show promise.

Most animal studies investigating the effect of chronic passive heat therapy on metabolic health and chronic low-grade inflammation have focussed on basal iHsp72 expression and its impact on insulin sensitivity (30, 56, 79, 127). In mice, heat therapy for 16 weeks increased basal iHsp72 expression in skeletal muscle concurrently with improved insulin sensitivity when compared with a sham control condition (30). To further support the importance of iHsp72 for insulin sensitivity, increasing iHsp72 expression by pharmacological means or genetic manipulation resulted in similar improvements in insulin sensitivity (30). A simultaneous increase in basal iHsp72 expression and improvement in insulin sensitivity was also reported in the studies by Gupte et al. (56) and Silverstein et al. (127). Mechanistically, the link between both adaptations following passive heating appears to involve the inhibition of JNK and NF- κ B activation (63). Indeed, Chung et al. (30) and Gupte et al. (56) reported reduced activation of these pathways following passive heat therapy. Moreover, in humans, low iHsp72 expression is associated with impaired insulin sensitivity, but also elevated JNK activity (30) (Figure 1).




Figure 1 - Chronic impact of passive heating on markers related to inflammation and glycaemic control: overview of evidence to date. A chronic positive energy balance, eventually resulting in obesity, leads to the activation of NF- κ B and JNK pathways. This results in an enhanced production of pro-inflammatory pathways and inhibits insulin receptor substrates, attenuating insulin sensitivity. Passive heating has the potential to counteract some of these negative adaptations, reducing inflammation and enhancing insulin sensitivity. eHsp72, extracellular heat shock protein 72; iHsp72, intracellular heat shock protein 72; IL-6, interleukin-6; IRS-1, insulin receptor substrate-1; JNK, c-Jun N-terminal kinase; NF- κ B, nuclear factor kappa B; TNF- α , tumour necrosis factor α .

In a series of studies, Kavanagh et al. (28, 79, 80) showed that the increase in iHsp72 can also lead to beneficial adaptations in non-human primates, a species genetically closer to humans. In these animals, two HWI sessions per week for five weeks increased basal iHsp72 expression in skeletal muscle, which was strongly associated with fasting blood glucose and the insulin responses during an intravenous glucose tolerance test (79). In keeping with the data derived from mice (30),

pharmacological induction of iHsp72 expression also increased iHsp72 expression and improved insulin sensitivity in non-human primates (80). Together, animal studies have highlighted the potential for chronic passive heating interventions to improve the inflammatory profile and metabolic health, possibly through the elevation of basal iHsp72 expression.

Epidemiological studies indicate that sauna bathing can reduce systemic inflammation (90), as well as all-cause mortality (91). Epidemiological data further show that habitual hot-spa bathing is linked to a lower incidence of hypertension and CVD (98). These findings are supported by controlled passive heating interventions investigating resting inflammatory and metabolic markers in humans, as summarised in Table 2. Hooper (70) showed that three weeks of HWI reduces fasting glucose and glycated haemoglobin concentration in people with T2DM. A reduction in fasting glucose concentration was also observed following two weeks of sauna therapy in patients with congestive heart failure (18), or two weeks of HWI in overweight (but otherwise healthy) individuals (66). Moreover, a two-week HWI intervention reduces plasma IL-6 concentration at rest in people with chronic heart failure (115), and four weeks of sauna therapy reduces IL-6 mRNA expression in leukocytes (156). In contrast, no changes in resting plasma concentration of IL-6 were found in healthy individuals following two- (66) or eight-week (22) HWI interventions, or nine days of passive heat acclimation (77).

The lack of improvements in inflammatory markers following repeated passive heating reported in some of these studies may be linked to the populations that were under investigation, which do not always present with an increased risk for metabolic ill-health *prior* to the chronic intervention (66). For other investigations, the reason

could also lie in the relatively modest body temperature increase that was induced in each session, or in the fact that the effect of the acclimation period was assessed on the day after the last passive heating session (77), possibly resulting in the assessment of acute instead of chronic effects. Despite these caveats, the existing evidence suggests that, providing

Table 2. The effect of chronic passive heating interventions on inflammatory and metabolic markers in humans.

Reference	Design	Population	Main outcomes
Brunt et al., 2018 (22)	8 weeks HWI with 36 sessions of 60 min in water set at 40.5°C	Healthy inactive men (N=6) and women (N=4) and sex-matched controls (N=10)	Serum concentration eHsp72 ↔, IL-6 ↔; peripheral blood mononuclear cell iHsp72 ↑
Biro et al., 2003 (18)	2 weeks of daily sauna bathing for 15 min at 60°C + blanket for 30 min	Healthy obese (BMI>30 kg/m ² ; N=10)	Fasting glucose concentration ↓
Ely et al., 2019 (39)	8–10 weeks HWI with 30 sessions of 60 min in water set to maintain 38.5–39.0°C of core temperature	Obese women with polycystic ovary syndrome (BMI = 41±1 kg/m ² ; N=9 intervention, N=9 resting control)	Fasting glucose concentration ↓, oral glucose tolerance test AUC ↓, adipose tissue insulin signalling ↑
Hafen et al., 2018 (58)	6 days of 2 h heating of skeletal muscle using pulsed wave diathermy	Healthy sedentary men (N=10) and women (N=10)	Skeletal muscle iHsp72 ↑
Hesketh et al., 2019 (64)	6 weeks of passive heating 40–50 min at room air of 40°C	Healthy sedentary (N=10 intervention, N=10 exercising control)	Oral glucose tolerance test AUC ↓
Hoekstra et al., 2018 (66)	2 weeks HWI with 10 sessions of 45–60 min in water set at 39°C	Healthy overweight sedentary men (BMI = 31±4 kg/m ² ; N=10 intervention, N=8 resting control)	Fasting glucose ↓, plasma concentration eHsp72 ↓, IL-6 ↔; monocyte iHsp72 ↔,
Hooper, 1999 (70)	3 weeks HWI with 18 sessions of 30 min in water set between 37 and 41°C	Patients with Type 2 Diabetes Mellitus (N=8)	Fasting glucose ↓, glycosylated haemoglobin concentration ↓
Kanikowska et al., 2012 (77)	9 sessions of 10 min HWI in water set at 42°C + blanket for 90 min in 40°C room	Healthy men (N=6)	Plasma concentration IL-6 ↔, TNF-α ↔
Kihara et al., 2002 (83)	2 weeks of daily sauna bathing for 10 min at 60°C + blanket for 30 min	Patients with chronic heart failure (N=20)	TNF-α ↔
Masuda et al., 2004 (102)	2 weeks of daily sauna bathing for 10 min at 60°C + blanket for 30 min	Patients with at least one coronary risk factor (N=14 intervention, N=14 resting control)	Fasting glucose ↔
Oyama et al., 2013 (115)	2 weeks HWI with 14 sessions of 10 min in water set at 40°C	Patients with chronic heart failure (N=16 intervention, N=16 resting control)	Plasma concentration IL-6 ↓, CRP ↓, TNF-α ↓
Zychowska et al., 2018 (155)	4 weeks of sauna bathing, 12 sessions, for 30 min at 98°C	Healthy men (N=22)	Leukocyte: <i>hsp72</i> mRNA expression ↓, IL-6 ↓*, IL-10 ↑

Abbreviations: AUC, area under the curve; BMI, body mass index; CRP, C-reactive protein; eHsp72, extracellular heat shock protein 72; HWI, hot water immersion; iHsp72, intracellular heat shock protein 72; IL, interleukin; mRNA, messenger ribonucleic acid; TNF-α, tumour necrosis factor-α. *trend for a decreased resting IL-6 mRNA expression.

sufficient thermal load, improvements in markers for glucose metabolism and chronic low-grade inflammation can be achieved in as little as two weeks. Because animal studies that have induced elevations in basal iHsp72 expression have used longer duration protocols (30, 127), this leaves the question of whether the observed improvements in glucose metabolism reported in humans are orchestrated by the actions of iHsp72. Indeed, no changes in iHsp72 in the presence of fasting glucose reductions have been found following two weeks of HWI in humans (66). Furthermore, as human studies often report more moderate increases in T_{core} than animal studies, it is not uncommon that acutely, iHsp72 remains unaffected (Table 1). It is therefore debatable whether acute increases in iHsp72 are required for a passive heating intervention to be beneficial in context of inflammation and glycaemic control. Other markers of inflammation (e.g., IL-6) do show acute perturbations in the absence of changes in iHsp72, and chronic interventions can improve glycaemic control using protocols of a duration and moderate heat stress too short or not sufficiently intense to acutely increase iHsp72 expression (Table 2).

Future research

The presented evidence supports a potential therapeutic role of passive heating interventions to reduce chronic low-grade inflammation that may particularly benefit clinical populations. However, such interventions bring their own challenges. For example, some populations exhibit impairments of thermoregulatory capacity, including those with T2DM (26) and those with SCI (55). Notwithstanding this, even in populations with normal thermoregulatory control, sweating is largely ineffective for regulating body temperature during HWI interventions due to the inability to decrease body temperature through evaporative heat loss. These clinical populations may therefore not be at a disadvantage *during* HWI. However, impaired thermoregulation affects the return of body temperature to normal *following* HWI (93), which may increase the risk in any emergency situations where a quick return of body temperature is warranted. Furthermore, heat interventions during which skin is exposed to air may induce accelerated elevations of body temperature in these at-risk populations (55). Heat therapy may also be associated with a higher risk for adverse events in the elderly and people with hypertension, T2DM, cardiovascular disease, or allergies (86). Indeed, heart disease is the main natural cause of death during sauna bathing, heat being a contributing factor in half of cases, and the main cause in a quarter of the deaths investigated in one particular study (81). It is further yet to be determined whether the acute elevations in postprandial glucose concentrations following HWI (92) occur in people with T2DM, and whether this might hence influence the feasibility of HWI interventions in this population. Therefore, protocols that have not been adapted and developed for at-risk populations must be carefully evaluated in order to avoid heat illness related events.

Developing protocols that are tolerable and, ideally, enjoyable, should form an important part of future investigations. For example, it could be questioned whether a 120-min HWI session inducing a rise in T_{core} of 2.0°C as studied by Oehler et

al. (114) is realistic to implement in a practical setting, as even a 60-min HWI session inducing a rise in T_{core} of 1.6°C can be perceived as uncomfortable (66) and physiologically straining (123). Therefore, protocols that induce minimal heat stress stimuli associated with improvements in health markers need to be identified. This may hence improve subjective perceptions of passive heating interventions. Similar to the approach taken in the development of exercise guidelines in a clinical population (SCI) (101), a focus might be put on finding minimal, rather than optimal, heat-doses to induce health benefits. Subjective perceptions may also be improved by targeting specific parts of the body rather than taking a whole-body approach; for example, local heating might reduce whole body heat strain. Such an approach can still result in noteworthy metabolic changes, as shown for targeted heating of one leg, resulting in increased glucose uptake when compared with the contralateral control leg (29). Alternatively, localised cooling might make whole-body heating protocols more tolerable. Finally, different populations (e.g., male/female, young/old, healthy/clinical) may present different characteristics regarding thermoregulation, heat perception and inflammatory profiles. Therefore, specific populations need investigating in detail, because the majority of evidence in controlled human laboratory studies is derived from young, healthy males.

Conclusions

Chronic low-grade inflammation is increasingly recognised in the aetiology of chronic diseases, such as T2DM and CVD. Although exercise can effectively reduce chronic low-grade inflammation, it may not be a feasible intervention to adhere to regularly for populations with reduced physical capacity and/or barriers to exercise. Because the increase in body temperature partly mediates the exercise-induced acute inflammatory response, passive heating strategies may have potential as an alternative or addition to exercise to reduce chronic low-grade inflammation. Indeed, the passive elevation of body temperature acutely influences a range of inflammatory markers that are affected by exercise, which is supported by human, animal and cell culture studies. A small but growing number of chronic passive heating interventions in humans have further explored its effect on inflammatory and metabolic markers. Whereas the literature on improvements of glycaemic control after repeated passive heating in humans is relatively convincing, consistent evidence for improvements of the inflammatory profile has so far been limited to animal studies. This limitation may be related to the reduced thermal load and the relatively short-duration chronic interventions that were investigated in humans. The development of effective and tolerable passive heating protocols to improve the inflammatory profile, alongside glycaemic control, using longer-term chronic interventions in humans should therefore be the aim of further investigations.

Acknowledgements

This report is independent research supported by the National Institute for Health Research Leicester Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research Leicester BRC or the Department of Health.

References

- Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 124: 783–801, 2006.
- Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, Smirnova N, Bergé M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Rautonen N, Sansonetti PJ, Burcelin R. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: Molecular mechanisms and probiotic treatment. *EMBO Mol Med* 3: 559–572, 2011.
- Amorim F, Yamada P, Robergs R, Schneider S, Moseley P. Effects of whole-body heat acclimation on cell injury and cytokine responses in peripheral blood mononuclear cells. *Eur J Appl Physiol* 111: 1609–1618, 2011.
- Amorim FT, Fonseca IT, Machado-Moreira CA, Magalhães F de C. Insights into the role of heat shock protein 72 to whole-body heat acclimation in humans. *Temperature* 2: 499–505, 2015.
- Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK- β links inflammation to obesity-induced insulin resistance. *Nat Med* 11: 191–198, 2005.
- Asea A. Initiation of the immune response by extracellular Hsp72: Chaperokine activity of Hsp72. *Curr Immunol Rev* 2: 209–215, 2006.
- Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. *Nat Med* 6: 435–442, 2000.
- Bachelet M, Mariéthoz E, Banzet N, Souil E, Pinot F, Polla CZ, Durand P, Bouchaert I, Polla BS. Flow cytometry is a rapid and reliable method for evaluating heat shock protein 70 expression in human monocytes. *Cell Stress Chaperones* 3: 168–176, 1998.
- Baker RG, Hayden MS, Ghosh S. NF- κ B, inflammation, and metabolic disease. *Cell Metab* 13: 11–22, 2011.
- Bakkum AJ, Paulson TA, Bishop NC, Goosey-Tolfrey VL, Stolwijk-Swuste JM, van Kuppevelt DJ, de Groot S, Janssen TW. Effects of hybrid cycle and handcycle exercise on cardiovascular disease risk factors in people with spinal cord injury: A randomized controlled trial. *J Rehabil Med* 47: 523–530, 2015.
- Bastard J, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. *Eur Cytokine Netw* 17: 4–12, 2006.
- Bastien M, Poirier P, Lemieux I, Després J-P. Overview of Epidemiology and Contribution of Obesity to Cardiovascular Disease. *Prog Cardiovasc Dis* 56: 369–381, 2014.
- Bauman WA, Spungen AM. Coronary heart disease in individuals with spinal cord injury: assessment of risk factors. *Spinal Cord* 46: 466–476, 2008.
- Bausinger H, Lipsker D, Ziyhan U, Manié S, Briand JP, Cazenave JP, Muller S, Haeuw JF, Ravanat C, de la Salle H, Hanau D. Endotoxin-free heat-shock protein 70 fails to induce APC activation. *Eur J Immunol* 32: 3708–3713, 2002.
- Baylis D, Bartlett DB, Patel HP, Roberts HC. Understanding how we age: insights into inflammaging. *Longev Heal* 2: 8, 2013.
- Beavers KM, Brinkley TE, Nicklas BJ. Effect of exercise training on chronic inflammation. *Clin Chim Acta* 411: 785–793, 2010.
- Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. *J Immunol (Baltimore, Md 1950)* 168: 3536–3542, 2002.
- Biro S, Masuda A, Kihara T, Tei C. Clinical implications of thermal therapy in lifestyle-related diseases. *Exp Biol Med (Maywood)* 228: 1245–1249, 2003.
- Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor- α reduces atherosclerosis in apolipoprotein E knockout mice. *Arterioscler Thromb Vasc Biol* 24: 2137–2142, 2004.
- Bruce CR, Carey AL, Hawley JA, Febbraio MA. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. *Diabetes* 52: 2338–2345, 2003.
- Brunt VE, Howard MJ, Francisco MA, Ely BR, Minson CT. Passive heat therapy improves endothelial function, arterial stiffness and blood pressure in sedentary humans. *J Physiol* 594: 5329–5342, 2016.
- Brunt VE, Wiedenfeld-Needham K, Comrada LN, Minson CT. Passive heat therapy protects against endothelial cell hypoxia-reoxygenation via effects of elevations in temperature and circulating factors. *J Physiol* 596: 4831–4845, 2018.
- Buchholz AC, Martin Ginis KA, Bray SR, Craven BC, Hicks AL, Hayes KC, Latimer AE, McColl MA, Potter PJ, Wolfe DL. Greater daily leisure time physical activity is associated with lower chronic disease risk in adults with spinal cord injury. *Appl Physiol Nutr Metab* 34: 640–647, 2009.
- Cangeri Di Naso F, Rosa Porto R, Sarubbi Fillmann H, Maggioni L, Vontobel Padoin A, Jacques Ramos R, Corá Mottin C, Bittencourt A, Anair Possa Marroni N, Ivo Homem De Bittencourt P. Obesity depresses the anti-inflammatory HSP70 pathway, contributing to NAFLD progression. *Obesity* 23: 120–129, 2015.
- Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. *Diabetes* 55: 2688–2697, 2006.
- Charkoudian N. Skin blood flow in adult human thermoregulation: How it works, when it does not, and why. *Mayo Clin. Proc.* 78 Elsevier Ltd: 603–612, 2003.
- Cheng JL, MacDonald MJ. Effect of heat stress on vascular outcomes in humans. *J Appl Physiol* 126: 771–781, 2019.
- Chichester L, Wylie AT, Craft S, Kavanagh K. Muscle heat shock protein 70 predicts insulin resistance with aging. *Journals Gerontol - Ser A Biol Sci Med Sci* 70: 155–162, 2015.
- Chiesa ST, Trangmar SJ, González-Alonso J. Temperature and blood flow distribution in the human leg during passive heat stress. *J Appl Physiol* 120: 1047–1058, 2016.
- Chung J, Nguyen AK, Henstridge DC, Holmes AG, Chan MH, Mesa JL, Lancaster GI, Southgate RJ, Bruce CR, Duffy SJ, Horvath I, Mestrlil R, Watt MJ, Hooper PL, Kingwell BA, Vigh

- L, Hevener A, Febbraio MA. HSP72 protects against obesity-induced insulin resistance. *Proc Natl Acad Sci U S A* 105: 1739–1744, 2008.
31. Costantino S, Paneni F, Cosentino F. Ageing, metabolism and cardiovascular disease. *J Physiol* 594: 2061–2073, 2016.
32. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE, Schauer PR. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. *Obes Surg* 14: 589–600, 2004.
33. Van Craenenbroeck AH, Van Ackeren K, Hoymans VY, Roeykens J, Verpooten GA, Vrints CJ, Couttenye MM, Van Craenenbroeck EM. Acute exercise-induced response of monocyte subtypes in chronic heart and renal failure. *Mediators Inflamm* 2014: doi: 10.1155/2014/216534, 2014.
34. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. *Diabetes* 25: 4–7, 2004.
35. Dasu MR, Devaraj S, Samuel P, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. *Diabetes Care* 33: 861–868, 2010.
36. Ding XZ, Fernandez-Prada CM, Bhattacharjee AK, Hoover DL. Over-expression of HSP-70 inhibits bacterial lipopolysaccharide-induced production of cytokines in human monocyte-derived macrophages. *Cytokine* 16: 210–219, 2001.
37. Dorsey CM, Lukas SE, Teicher MH, Harper D, Winkelman JW, Cunningham SL, Satlin A. Effects of passive body heating on the sleep of older female insomniacs. *J Geriatr Psychiatry Neurol* 9: 83–90, 1996.
38. Duncan BB. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. *Diabetes* 52: 1799–1805, 2003.
39. Ely BR, Clayton ZS, McCurdy CE, Pfeiffer J, Needham KW, Comrada LN, Minson CT. Heat therapy improves glucose tolerance and adipose tissue insulin signaling in obese women with polycystic ovary syndrome. *Am J Physiol Metab* 317: E172–E182, 2019.
40. Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol* 115: 911–920, 2005.
41. Faulkner SH, Jackson S, Fatania G, Leicht CA. The effect of passive heating on heat shock protein 70 and interleukin-6: A possible treatment tool for metabolic diseases? *Temperature* 4: 292–304, 2017.
42. Febbraio MA, Ott P, Nielsen HB, Steensberg A, Keller C, Krstrup P, Secher NH, Pedersen BK. Exercise induces hepatosplanchnic release of heat shock protein 72 in humans. *J Physiol* 544: 957–962, 2002.
43. Febbraio MA, Pedersen BK. Contraction-induced myokine production and release: Is skeletal muscle an endocrine organ? *Exerc Sport Sci Rev* 33: 114–119, 2005.
44. Fehrenbach E, Niess AM, Veith R, Dickhuth HH, Northoff H. Changes of HSP72-expression in leukocytes are associated with adaptation to exercise under conditions of high environmental temperature. *J Leukoc Biol* 69: 747–754, 2001.
45. Fink WJ, Costill DL, Van Handel PJ. Leg muscle metabolism during exercise in the heat and cold. *Eur J Appl Physiol* 34: 183–190, 1975.
46. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? *Exerc Immunol Rev* 12: 6–33, 2006.
47. Flynn MG, McFarlin BK. Toll-like receptor 4: link to the anti-inflammatory effects of exercise? *Exerc Sport Sci Rev* 34: 176–181, 2006.
48. Gabai VL, Meriin AB, Mosser DD, Caron AW, Rits S, Shifrin VI, Sherman MY. Hsp70 prevents activation of stress kinases: A novel pathway of cellular thermotolerance. *J Biol Chem* 272: 18033–18037, 1997.
49. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. *J Biol Chem* 278: 174–179, 2003.
50. Geiger PC, Gupte AA. Heat shock proteins are important mediators of skeletal muscle insulin sensitivity. *Exerc Sport Sci Rev* 39: 34–42, 2011.
51. Gibson OR, Dennis A, Parfitt T, Taylor L, Watt PW, Maxwell NS. Extracellular Hsp72 concentration relates to a minimum endogenous criteria during acute exercise-heat exposure. *Cell Stress Chaperones* 19: 389–400, 2014.
52. Gibson OR, Tuttle JA, Watt PW, Maxwell NS, Taylor L. Hsp72 and Hsp90α mRNA transcription is characterised by large, sustained changes in core temperature during heat acclimation. *Cell Stress Chaperones* 21: 1021–1035, 2016.
53. Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. *Brain Behav Immun* 70: 61–75, 2018.
54. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. *Nat Rev* 11: 607–615, 2011.
55. Griggs KE, Havenith G, Price MJ, Goosey-Tolfrey VL. Evaporative heat loss insufficient to attain heat balance at rest in individuals with a spinal cord injury at high ambient temperature. *J Appl Physiol* 127: 995–1004, 2019.
56. Gupte AA, Bomhoff GL, Swerdlow RH, Geiger PC. Heat treatment improves glucose tolerance and prevents skeletal muscle insulin resistance in rats fed a high-fat diet. *Diabetes* 58: 567–578, 2009.
57. Gupte AA, Bomhoff GL, Touchberry CD, Geiger PC. Acute heat treatment improves insulin-stimulated glucose uptake in aged skeletal muscle. *J Appl Physiol* 110: 451–457, 2011.
58. Hafen PS, Preece CN, Sorensen JR, Hancock CR, Hyldahl RD. Repeated exposure to heat stress induces mitochondrial adaptation in human skeletal muscle. *J Appl Physiol* 125: 1447–1455, 2018.
59. Hamer M, Sabia S, Batty GD, Shipley MJ, Tabák AG, Singh-Manoux A, Kivimaki M. Physical activity and inflammatory markers over 10 years: Follow-up in men and women from the whitehall II cohort study. *Circulation* 126: 928–933, 2012.
60. Hashizaki T, Nishimura Y, Teramura K, Umemoto Y, Shibasaki M, Leicht CA, Kouda K, Tajima F. Differences in serum IL-6 response after 1 °C rise in core body temperature in individuals with spinal cord injury and cervical spinal cord injury during local heat stress. *Int J Hyperth* 35: 541–547, 2018.
61. Henstridge DC, Bruce CR, Drew BG, Tory K, Kolonics A, Estevez E, Chung J, Watson N, Gardner T, Lee-Young RS, Connor T, Watt MJ, Carpenter K, Hargreaves M, McGee SL, Hevener AL, Febbraio MA. Activating HSP72 in rodent skeletal muscle increases mitochondrial number and oxidative capacity and decreases insulin resistance. *Diabetes* 63: 1881–1894, 2014.

62. Henstridge DC, Forbes JM, Penfold SA, Formosa MF, Dougherty S, Gasser A, de Courten MP, Cooper ME, Kingwell BA, de Courten B. The relationship between heat shock protein 72 expression in skeletal muscle and insulin sensitivity is dependent on adiposity. *Metabolism* 59: 1556–1561, 2010.
63. Henstridge DC, Whitham M, Febbraio MA. Chaperoning to the metabolic party: The emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes. *Mol Metab* 3: 781–793, 2014.
64. Hesketh K, Shepherd SO, Strauss JA, Low DA, Cooper RJ, Wagenmakers AJM, Cocks M. Passive heat therapy in sedentary humans increases skeletal muscle capillarization and eNOS content but not mitochondrial density or GLUT4 content. *Am J Physiol Circ Physiol* 317: H114–H123, 2019.
65. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. *Nature* 420: 333–336, 2002.
66. Hoekstra SP, Bishop NC, Faulkner SH, Bailey SJ, Leicht CA. The acute and chronic effects of hot water immersion on inflammation and metabolism in sedentary, overweight adults. *J Appl Physiol* 125: 2008–2018, 2018.
67. Hoekstra SP, Westerman MN, Beke F, Bishop NC, Leicht CA. Modality-specific training adaptations – do they lead to a dampened acute inflammatory response to exercise? *Appl Physiol Nutr Metab* 44: 965–972, 2019.
68. Hoekstra SP, Wright AKA, Bishop NC, Leicht CA. The effect of temperature and heat shock protein 72 on the ex vivo acute inflammatory response in monocytes. *Cell Stress Chaperones* 24: 461–467, 2019.
69. Hong S, Mills PJ. Effects of an exercise challenge on mobilization and surface marker expression of monocyte subsets in individuals with normal vs. elevated blood pressure. *Brain Behav Immun* 22: 590–599, 2008.
70. Hooper PL. Hot-tub therapy for type 2 diabetes mellitus. *N Engl J Med* 341: 924–925, 1999.
71. Hooper PL, Balogh G, Rivas E, Kavanagh K, Vigh L. The importance of the cellular stress response in the pathogenesis and treatment of type 2 diabetes. *Cell Stress Chaperones* 19: 447–464, 2014.
72. Hotamisligil GS. Inflammatory pathways and insulin action. *Int J Obes* 27: S53–S55, 2003.
73. Hotamisligil GS. Inflammation and metabolic disorders. *Nature* 444: 860–867, 2006.
74. Iguchi M, Littmann AE, Chang SH, Wester LA, Knipper JS, Shields RK. Heat stress and cardiovascular, hormonal, and heat shock proteins in humans. *J Athl Train* 47: 184–190, 2012.
75. Johnson JD, Fleshner M. Releasing signals, secretory pathways, and immune function of endogenous extracellular heat shock protein 72. *J Leukoc Biol* 79: 425–434, 2006.
76. Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. *Int Immunol* 27: 21–29, 2015.
77. Kanikowska D, Sato M, Sugenoja J, Iwase S, Shimizu Y, Nishimura N, Inukai Y. No effects of acclimation to heat on immune and hormonal responses to passive heating in healthy volunteers. *Int J Biometeorol* 56: 107–112, 2012.
78. Kashiwagi M, Imanishi T, Ozaki Y, Satogami K, Masuno T, Wada T, Nakatani Y, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Kitabata H, Akasaka T. Differential expression of Toll-like receptor 4 and human monocyte subsets in acute myocardial infarction. *Atherosclerosis* 221: 249–253, 2011.
79. Kavanagh K, Davis AT, Jenkins KA, Flynn DM. Effects of heated hydrotherapy on muscle HSP70 and glucose metabolism in old and young vervet monkeys. *Cell Stress Chaperones* 21: 717–725, 2016.
80. Kavanagh K, Flynn DM, Jenkins K a, Zhang L, Wagner JD. Restoring HSP70 deficiencies improves glucose tolerance in diabetic monkeys. *Am J Physiol Endocrinol Metab* 300: E894–E901, 2011.
81. Kenttämies A, Karkola K. Death in sauna. *J Forensic Sci* 53: 724–729, 2008.
82. Kiang JG, Tsokos GC. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. *Pharmacol Ther* 80: 183–201, 1998.
83. Kihara T, Biro S, Imamura M, Yoshifuku S, Takasaki K, Ikeda Y, Otsuji Y, Minagoe S, Toyama Y, Tei C. Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. *J Am Coll Cardiol* 39: 754–759, 2002.
84. King YT, Lin CS, Lin JH, Lee WC. Whole-body hyperthermia-induced thermotolerance is associated with the induction of heat shock protein 70 in mice. *J Exp Biol* 205: 273–278, 2002.
85. Krause M, Keane K, Rodrigues-Krause J, Crognale D, Egan B, De Vito G, Murphy C, Newsholme P. Elevated levels of extracellular heat-shock protein 72 (eHSP72) are positively correlated with insulin resistance in vivo and cause pancreatic β -cell dysfunction and death in vitro. *Clin Sci* 126: 739–752, 2014.
86. Krause M, Ludwig MS, Heck TG, Takahashi HK. Heat shock proteins and heat therapy for type 2 diabetes: pros and cons. *Curr Opin Clin Nutr Metab Care* 18: 374–380, 2015.
87. Kuennen M, Gillum T, Dokladny K, Bedrick E, Schneider S, Moseley P. Thermotolerance and heat acclimation may share a common mechanism in humans. *AJP Regul Integr Comp Physiol* 301: R524–R533, 2011.
88. Laing SJ, Jackson AR, Walters R, Lloyd-Jones E, Whitham M, Maassen N, Walsh NP. Human blood neutrophil responses to prolonged exercise with and without a thermal clamp. *J Appl Physiol* (Bethesda, Md 1985) 104: 20–26, 2008.
89. Lancaster GI, Khan Q, Drysdale P, Wallace F, Jeukendrup AE, Drayson MT, Gleeson M. The physiological regulation of toll-like receptor expression and function in humans. *J Physiol* 563: 945–955, 2005.
90. Laukkanen JA, Laukkanen T. Sauna bathing and systemic inflammation. *Eur J Epidemiol* 33: 351–353, 2018.
91. Laukkanen T, Khan H, Zaccardi F, Laukkanen JA, J V, S K. Association Between Sauna Bathing and Fatal Cardiovascular and All-Cause Mortality Events. *JAMA Intern Med* 175: 542–548, 2015.
92. Leicht CA, James LJ, Briscoe JHB, Hoekstra SP. Hot water immersion acutely increases postprandial glucose concentrations. *Physiol Rep* 7(20):e14223. doi: 10.14814/phy2.14223, 2019.
93. Leicht CA, Kouda K, Umemoto Y, Banno M, Kinoshita T, Moriki T, Nakamura T, Bishop NC, Goosey-Tolfrey VL, Tajima F. Hot water immersion induces an acute cytokine response in cervical spinal cord injury. *Eur J Appl Physiol* 115: 2243–2252, 2015.
94. Leicht CA, Paulson TAW, Goosey-Tolfrey VL, Bishop NC. Arm and intensity-matched leg exercise induce similar inflammatory responses. *Med Sci Sports Exerc* 48: 1161–1168, 2016.

95. Leung FP, Yung LM, Laher I, Yao X, Chen ZY, Huang Y. Exercise, vascular wall and cardiovascular diseases. *Sport Med* 38: 1009–1024, 2008.
96. Maachi M, Piéroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, Capeau J, Bastard JP. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF α , leptin and IL-6 levels in obese women. *Int J Obes* 28: 993–997, 2004.
97. Macera CA, Cavanaugh A, Bellettiere J. State of the art review: physical activity and older adults. *Am J Lifestyle Med* 11: 42–57, 2017.
98. Maeda T, Mimori K, Suzuki S, Horiuchi T, Makino N. Preventive and promotive effects of habitual hot spa-bathing on the elderly in Japan. *Sci Rep* 8: 133, 2018.
99. Marshall HC, Campbell SA, Roberts CW, Nimmo MA. Human physiological and heat shock protein 72 adaptations during the initial phase of humid-heat acclimation. *J Therm Biol* 32: 341–348, 2007.
100. Martin Ginis KA, Latimer AE, Arbour-Nicitopoulos KP, Buchholz AC, Bray SR, Craven BC, Hayes KC, Hicks AL, McColl MA, Potter PJ, Smith K, Wolfe DL. Leisure time physical activity in a population-based sample of people with spinal cord injury part I: demographic and injury-related correlates. *Arch Phys Med Rehabil* 91: 722–728, 2010.
101. Martin Ginis KA, van der Scheer JW, Latimer-Cheung AE, Barrow A, Bourne C, Carruthers P, Bernardi M, Ditor DS, Gaudet S, de Groot S, Hayes KC, Hicks AL, Leicht CA, Lexell J, Macaluso S, Manns PJ, McBride CB, Noonan VK, Pomerleau P, Rimmer JH, Shaw RB, Smith B, Smith KM, Steeves JD, Tussler D, West CR, Wolfe DL, Goosey-Tolfrey VL. Evidence-based scientific exercise guidelines for adults with spinal cord injury: an update and a new guideline. *Spinal Cord* 56: 308–321, 2018.
102. Masuda A, Miyata M, Kihara T, Minagoe S, Tei C. Repeated sauna therapy reduces urinary 8-epi-prostaglandin F(2 α). *Jpn Heart J* 45: 297–303, 2004.
103. de Matos MA, Duarte TC, Ottone V de O, Sampaio PF da M, Costa KB, de Oliveira MFA, Moseley PL, Schneider SM, Coimbra CC, Brito-Melo GEA, Magalhães F de C, Amorim FT, Rocha-Vieira E. The effect of insulin resistance and exercise on the percentage of CD16⁺ monocyte subset in obese individuals. *Cell Biochem Funct* 34: 209–216, 2016.
104. McCarty MF, Barroso-Aranda J, Contreras F. Regular thermal therapy may promote insulin sensitivity while boosting expression of endothelial nitric oxide synthase--effects comparable to those of exercise training. *Med Hypotheses* 73: 103–105, 2009.
105. McClung JP, Hasday JD, He JR, Montain SJ, Cheuvront SN, Sawka MN, Singh IS. Exercise-heat acclimation in humans alters baseline levels and ex vivo heat inducibility of HSP72 and HSP90 in peripheral blood mononuclear cells. *Am J Physiol Integr Comp Physiol* 294: R185–R191, 2008.
106. Meldrum KK, Burnett AL, Meng X, Misseri R, Shaw MBK, Gearhart JP, Meldrum DR. Liposomal delivery of heat shock protein 72 into renal tubular cells blocks nuclear factor- κ B activation, tumor necrosis factor- α production, and subsequent ischemia-induced apoptosis. *Circ Res* 92: 293–299, 2003.
107. Morse LR, Stolzmann K, Nguyen HP, Jain NB, Zayac C, Gagnon DR, Tun CG, Garshick E. Association Between Mobility Mode and C-Reactive Protein Levels in Men With Chronic Spinal Cord Injury. *Arch Phys Med Rehabil* 89: 726–731, 2008.
108. Morton JP, MacLaren DPM, Cable NT, Bongers T, Griffiths RD, Campbell IT, Evans L, Kayani A, McArdle A, Drust B. Time course and differential responses of the major heat shock protein families in human skeletal muscle following acute nondamaging treadmill exercise. *J Appl Physiol* 101: 176–82, 2006.
109. Morton JP, MacLaren DPM, Cable NT, Campbell IT, Evans L, Bongers T, Griffiths RD, Kayani AC, McArdle A, Drust B. Elevated core and muscle temperature to levels comparable to exercise do not increase heat shock protein content of skeletal muscle of physically active men. *Acta Physiol* 190: 319–327, 2007.
110. Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B. Non-Classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematosus. *Sci Rep* 5: 1–14, 2015.
111. Njemini R, Demanet C, Mets T. Inflammatory status as an important determinant of heat shock protein 70 serum concentrations during aging. *Biogerontology* 5: 31–38, 2004.
112. Noble EG, Milne KJ, Melling CWJ. Heat shock proteins and exercise: a primer. *Appl Physiol Nutr Metab* 33: 1050–1075, 2008.
113. Obi S, Nakajima T, Hasegawa T, Kikuchi H, Oguri G, Takahashi M, Nakamura F, Yamasoba T, Sakuma M, Toyoda S, Tei C, Inoue T. Heat induces interleukin-6 in skeletal muscle cells via TRPV1/PKC/CREB pathways. *J Appl Physiol* 122: 683–694, 2017.
114. Oehler R, Pusch E, Zellner M, Dungal P, Hergovics N, Homoncik M, Eliassen MM, Brabec M, Roth E. Cell type-specific variations in the induction of hsp70 in human leukocytes by feverlike whole body hyperthermia. *Cell Stress Chaperones* 6: 306–315, 2001.
115. Oyama J-I, Kudo Y, Maeda T, Node K, Makino N. Hyperthermia by bathing in a hot spring improves cardiovascular functions and reduces the production of inflammatory cytokines in patients with chronic heart failure. *Heart Vessels* 28: 173–178, 2013.
116. Ozaki Y, Imanishi T, Hosokawa S, Nishiguchi T, Taruya A, Tanimoto T, Kuroi A, Yamano T, Matsuo Y, Ino Y, Kitabata H, Kubo T, Tanaka A, Akasaka T. Association of toll-like receptor 4 on human monocyte subsets and vulnerability characteristics of coronary plaque as assessed by 64-slice multidetector computed tomography. *Circ J* 81: 837–845, 2017.
117. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. *Physiol Rev* 88: 1379–1406, 2008.
118. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. *J Appl Physiol* (Bethesda, Md 1985) 98: 1154–1162, 2005.
119. Pockley AG, Georgiades A, Thulin T, De Faire U, Frostegård J. Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. *Hypertension* 42: 235–238, 2003.
120. Pradhan A.D., Manson J.E., Rifai N., Buring J. E. A, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *J Am Med Assoc* 286: 327–34, 2001.
121. Raison CL, Knight JM, Pariante C. Interleukin (IL)-6: A good kid hanging out with bad friends (and why sauna is good for health). *Brain Behav Immun* 73: 1–2, 2018.
122. Rhind SG, Gannon GA, Shephard RJ, Buguet A, Shek PN, Radomski MW. Cytokine induction during exertional hyper-

- thermia is abolished by core temperature clamping: neuroendocrine regulatory mechanisms. *Int J Hyperthermia* 20: 503–516, 2004.
123. Rivas E, Newmire DE, Crandall CG, Hooper PL, Ben-Ezra V. An acute bout of whole body passive hyperthermia increases plasma leptin, but does not alter glucose or insulin responses in obese type 2 diabetics and healthy adults. *J Therm Biol* 59: 26–33, 2016.
 124. Rosety-Rodriguez M, Camacho A, Rosety I, Fornieles G, Rosety MA, Diaz AJ, Bernardi M, Rosety M, Ordonez FJ. Low-grade systemic inflammation and leptin levels were improved by arm cranking exercise in adults with chronic spinal cord injury. *Arch Phys Med Rehabil* 95: 297–302, 2014.
 125. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. *J. Clin. Invest.* 127: 1–4, 2017.
 126. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical activity/exercise and type 2 diabetes: A consensus statement from the American Diabetes Association. *Diabetes Care* 29: 1433–1438, 2006.
 127. Silverstein MG, Ordanes D, Wylie AT, Files DC, Milligan C, Presley TD, Kavanagh K. Inducing muscle heat shock protein 70 improves insulin sensitivity and muscular performance in aged mice. *Journals Gerontol - Ser A Biol Sci Med Sci* 70: 800–808, 2014.
 128. Simar D, Jacques A, Caillaud C. Heat shock proteins induction reduces stress kinases activation, potentially improving insulin signalling in monocytes from obese subjects. *Cell Stress Chaperones* 17: 615–621, 2012.
 129. Simar D, Malatesta D, Koechlin C, Cristol JP, Vendrell JP, Caillaud C. Effect of age on Hsp72 expression in leukocytes of healthy active people. *Exp Gerontol* 39: 1467–1474, 2004.
 130. Singh R, Kølvrå S, Bross P, Jensen UB, Gregersen N, Tan Q, Knudsen C, Rattan SIS. Reduced heat shock response in human mononuclear cells during aging and its association with polymorphisms in HSP70 genes. *Cell Stress Chaperones* 11: 208–215, 2006.
 131. Starkie RL, Hargreaves M, Rolland J, Febbraio MA. Heat stress, cytokines, and the immune response to exercise. *Brain Behav Immun* 19: 404–412, 2005.
 132. Steensberg A, Fischer CP, Keller C, Møller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. *Am J Physiol Metab* 285: E433–E437, 2003.
 133. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. *J Physiol* 548: 631–638, 2003.
 134. Steensberg A, Van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. *J Physiol* 529: 237–242, 2000.
 135. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M. IL-10, IL-6, and TNF- α : Central factors in the altered cytokine network of uremia - The good, the bad, and the ugly. *Kidney Int* 67: 1216–1233, 2005.
 136. Steppich B, Dayyani F, Gruber R, Lorenz R, Mack M, Ziegler-Heitbrock HWL. Selective mobilization of CD14+CD16+ monocytes by exercise. *Am J Physiol - Cell Physiol* 279: C578–C586, 2000.
 137. Sun F, Norman IJ, While AE. Physical activity in older people: a systematic review. *BMC Public Health* 13: 449, 2013.
 138. Thomas KN. Harnessing heat for health: A clinical application of heat stress. *Temperature* 4: 208–210, 2017.
 139. Timmerman KL, Flynn MG, Coen PM, Markofski MM, Pence BD. Exercise training-induced lowering of inflammatory (CD14+CD16+) monocytes: a role in the anti-inflammatory influence of exercise? *J Leukoc Biol* 84: 1271–1278, 2008.
 140. Totosty de Zepetnek JO, Pelletier CA, Hicks AL, MacDonald MJ. Following the physical activity guidelines for adults with spinal cord injury for 16 weeks does not improve vascular health: a randomized controlled trial. *Arch Phys Med Rehabil* 96: 1566–1575, 2015.
 141. Tuttle JA, Christmas BCR, Gibson OR, Barrington JH, Hughes DC, Castle PC, Metcalfe AJ, Midgley AW, Pearce O, Kabir C, Rayanmarakar F, Al-Ali S, Lewis MP, Taylor L. The Hsp72 and Hsp90 α mRNA responses to hot downhill running are reduced following a prior bout of hot downhill running, and occur concurrently within leukocytes and the vastus lateralis. *Front Physiol* 8: 473, 2017.
 142. Viana JL, Kosmadakis GC, Watson EL, Bevington A, Feehally J, Bishop NC, Smith AC. Evidence for Anti-Inflammatory Effects of Exercise in CKD. *J Am Soc Nephrol* 25: 2121–2130, 2014.
 143. Vissers M, van den Berg-Emons R, Sluis T, Bergen M, Stam H, Bussmann H. Barriers to and facilitators of everyday physical activity in persons with a spinal cord injury after discharge from the rehabilitation centre. *J Rehabil Med* 40: 461–467, 2008.
 144. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. *Obes Res* 9: 414–417, 2001.
 145. Welc SS, Judge AR, Clanton TL. Skeletal muscle interleukin-6 regulation in hyperthermia. *Am J Physiol Physiol* 305: 406–413, 2013.
 146. Welc SS, Phillips NA, Oca-Cossio J, Wallet SM, Chen DL, Clanton TL. Hyperthermia increases interleukin-6 in mouse skeletal muscle. *Am J Physiol Physiol* 303: C455–C466, 2012.
 147. Welsh P, Grassia G, Botha S, Sattar N, Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? *Br. J. Pharmacol.* 174: 3898–3913, 2017.
 148. Whitham M, Fortes MB. Heat shock protein 72: release and biological significance during exercise. *Front Biosci* 13: 1328–1339, 2008.
 149. Whitham M, Laing SJ, Jackson A, Maassen N, Walsh NP. Effect of exercise with and without a thermal clamp on the plasma heat shock protein 72 response. *J Appl Physiol (Bethesda, Md 1985)* 103: 1251–1256, 2007.
 150. Wild S, Roglic G, Green A, Sicree R, King H. Estimates for the year 2000 and projections for 2030. *World Health* 27: 1047–1053, 2004.
 151. Wilmut EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, Khunti K, Yates T, Biddle SJH. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: Systematic review and meta-analysis. *Diabetologia* 55: 2895–2905, 2012.
 152. Wilund KR. Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease? *Clin Sci (Lond)* 112: 543–555, 2007.

153. Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. *Immunol Res* 53: 41–57, 2012.
154. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Derek N, Leenen PJM, Liu Y, Macpherson G, Randolph GJ, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB, Hart DN. Nomenclature of monocytes and dendritic cells in blood. *116*: 5–7, 2010.
155. Żychowska M, Nowak-Zaleska A, Chruściński G, Zaleski R, Mieszkowski J, Niespodziński B, Tymański R, Kochanowicz A. Association of high cardiovascular fitness and the rate of adaptation to heat stress. *Biomed Res Int* 2018: 1685368, 2018.
156. Żychowska M, Półrola P, Chruściński G, Zielińska J, Góral-Półrola J. Effects of sauna bathing on stress-related genes expression in athletes and non-athletes. *Ann Agric Environ Med* 24: 104–107, 2017.